NRG-GI008: Colon Adjuvant chemotherapy based on evaluation of residual Disease

Inclusion:

• Histologically/pathologically confirmed Stage IIB, IIC, or Stage III colon adenocarcinoma with R0 resection.

• Interval between surgery (post-op day 7) and study entry must be no more than 60 days

• Must be a candidate for all potential agents used in this trial (5FU, LV, oxaliplatin and irinotecan)

• Lesion at least 12 cm from anal verge on colonoscopy or above peritoneal reflection on path or op report

Exclusion:

• Colon cancer histology other than adenocarcinoma

• Radiographic evidence of overt metastatic disease

• Prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as tx for colorectal cancer (e.g. primary colon adenocarcinomas for which tx with neoadjuvant chemo and/or radiation is warranted are not permitted)

• Rectal adenocarcinomas synchronous primary rectal and/or colon cancers

• Peripheral neuropathy ≥ grade 2

• Patients whose tumors are MSI-H or dMMR